Percentage of patients with PFS2/PFS1≥1.3^{a} | |||||
---|---|---|---|---|---|

Univariable | Multivariable | ||||

Parameters | Percentage | Wald | P | Wald | P |

Matched | 8.16 | 0.004 | 3.62 | 0.057 | |

Yes (n = 53) | 45.3% | ||||

No (n = 57) | 19.3% | ||||

Breast | 11.2 | 0.001 | 6.52 | 0.011 | |

Yes (n = 35) | 54.3% | ||||

No (n = 75) | 21.3% | ||||

Brain | 2.03 | 0.154 | NA | NA | |

Yes (n = 7) | 57% | ||||

No (n = 103) | 30% | ||||

Gastrointestinal | 5.36 | 0.021 | NA | NA | |

Yes (n = 22) | 9% | ||||

No (n = 88) | 37.5% | ||||

Genitourinary | 1.08 | 0.298 | NA | NA | |

Yes (n = 15) | 20% | ||||

No (n = 95) | 34% | ||||

Head and neck | 0.78 | 0.377 | NA | NA | |

Yes (n = 14) | 21% | ||||

No (n = 96) | 33% | ||||

Lung | 1.00 | 0.317 | NA | NA | |

Yes (n = 11) | 18% | ||||

No (n = 99) | 33% | ||||

Skin/melanoma | 0.160 | 0.689 | NA | NA | |

Yes (n = 5) | 40% | ||||

No (n = 105) | 31% | ||||

Metastasis at time of biopsy | 1.66 | 0.197 | NA | NA | |

Yes (n = 86) | 35% | ||||

No (n = 24) | 21% | ||||

Single agent (n = 62) | 34% | 0.276 | 0.600 | NA | NA |

Combination (n = 48) | 29% | ||||

OS analysis^{b} | |||||

Univariable | Multivariable | ||||

Parameters | Median (Mo, 95%CI) | χ^{2} | P | Wald | P |

Matched | 0.67 | 0.414 | NA | NA | |

Yes (n = 87) | 14.4 (10.8–17.9) | ||||

No (n = 93) | 11.4 (5.8–17.0) | ||||

Breast | 2.23 | 0.136 | NA | NA | |

Yes (n = 60) | 15.7 (6.1–25.4) | ||||

No (n = 120) | 11.1 (7.2–15.1) | ||||

Brain | 0.19 | 0.666 | NA | NA | |

Yes (n = 15) | 14.0 (5.3–22.6) | ||||

No (n = 165) | 11.9 (8.1–15.7) | ||||

Gastrointestinal | 0.89 | 0.346 | NA | NA | |

Yes (n = 35) | 12.7 (5.6–19.7) | ||||

No (n = 145) | 14.0 (10.0–17.9) | ||||

Genitourinary | 0.002 | 0.963 | NA | NA | |

Yes (n = 22) | 10.0 (7.5–12.6) | ||||

No (n = 158) | 14.0 (10.6–17.3) | ||||

Head and neck | 2.01 | 0.156 | NA | NA | |

Yes (n = 16) | 8.4 (5.9–11.0) | ||||

No (n = 164) | 14.4 (11.0–17.7) | ||||

Lung | 0.042 | 0.837 | NA | NA | |

Yes (n = 16) | 9.9 (—) | ||||

No (n = 164) | 12.7 (9.0–16.3) | ||||

Skin/melanoma | 0.023 | 0.878 | NA | NA | |

Yes (n = 11) | 10.2 (7.3–13.0) | ||||

No (n = 169) | 12.7 (9.0–16.3) | ||||

Metastasis at time of diagnostic | 0.008 | 0.927 | NA | NA | |

Yes (n = 138) | 12.7(—) | ||||

No (n = 42) | 12.6 (8.9–16.4) | ||||

Therapy was 1st line | 3.84 | 0.050 | 5.48 | 0.019 | |

Yes (n = 43) | 15.5 (—) | ||||

No (n = 137) | 10.6 (8.4–12.9) | ||||

Single agent (n = 95) | 11.1 (5.8–16.3) | 0.463 | 0.496 | NA | NA |

Combination (n = 85) | 14.0 (11.1–16.8) | ||||

CDKN2A | 3.16 | 0.078 | 2.83 | 0.093 | |

Yes (n = 34) | 10.5 (6.9–14.1) | ||||

No (n = 146) | 14.7 (8.9–20.6) | ||||

TP53 | 3.77 | 0.052 | NA | NA | |

Yes (n = 87) | 10.6 (8.8–12.5) | ||||

No (n = 93) | 15.7 (10.7–20.7) | ||||

PTEN | 0.297 | 0.586 | NA | NA | |

Yes (n = 19) | 8.4 (2.3–14.5) | ||||

No (n = 161) | 14.0 (10.4–17.6) | ||||

Matching-score > 0.2 (n = 122) | 15.7 (—) | 3.62 | 0.057 | 4.24 | 0.040 |

Matching-score ≤ 0.2 (n = 58) | 10.6 (8.1–13.2) |

↵

^{a}Logistic regression analysis was used (univariables and multivariable); variables with*P*< 0.05 were included in the multivariable backward conditional model. The Wald test is a way of testing the significance of variables in a statistical model; the higher the Wald, the higher the association in the model. When the propensity score was added as a covariate with “matched vs. not,” the*P*value for “matched vs. not” was 0.087 (Wald = 2.93). With the inverse propensity weighting method, the*P*value for “matched vs. not” was 0.079 (Wald = 3.15).↵

^{b}*P*values were computed using the Kaplan–Meier method (log-rank test for univariable and Cox regression for multivariate analysis); variables with*P*< 0.2 were included in the Cox regression model (multivariable, backward conditional model). —, in some cases, the 95% CI could not be computed. The χ^{2}and Wald values test the significance of variables in the statistical model; the higher the χ^{2}or Wald, the higher the association in the model. The matching-score was calculated by dividing the number derived from the matches in each patient (numerator) by the number of aberrations (denominator). The cutoff value of 0.2 was chosen with the minimum*P*value criteria (21).